Since 2017, large outbreaks of hepatitis A among adults have been occurring in a number of US cities and states, resulting in increased demand for vaccine. Initially, supplies of adult hepatitis A vaccine in the US were constrained. In response, CDC took a number of steps to mitigate the supply issues. Specifically, CDC (1) worked directly with public health officials in affected jurisdictions to provide guidance about targeting vaccine in response to local epidemiology; (2) collaborated with manufacturers to understand options for managing supplies in the private sector and increasing national supply; (3) implemented ordering controls in the public sector; and (4) increased vaccine availability on CDC’s adult vaccine contracts.
Nevertheless a shortage has formed in 2020-2021
IHME model extends to November 01, 2021 – predicts Fall upswing in mortality
Mortality expected to increase 3x from current levels.
Increase in excess deaths attributed to spread of Delta variant.